ACADIA Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

  • ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019
    on July 17, 2019 at 1:00 pm

    ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the second quarter ended June 30, 2019 on Wednesday, July 31, 2019, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Wednesday, July 31, 2019, at 4:30 p.m. Eastern Time to discuss ACADIA’s financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067 for international callers (reference passcode 1288895). […]

  • Does ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Salary Reflect Performance?
    on July 11, 2019 at 10:36 am

    Steve Davis has been the CEO of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) since 2015. This analysis aims first to... […]

  • New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners
    on June 25, 2019 at 12:50 pm

    NEW YORK and SAN DIEGO, June 25, 2019 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) and ACADIA Pharmaceuticals announce the launch of "Parkinson's IQ + You," a series of local events across the United States in 2019 and 2020 to educate and empower patients and their care partners. Parkinson's IQ + You will host live events to support Parkinson's families in learning more about the disease, the elements of a comprehensive care team, communication between patients and their doctors, the latest PD treatments and those in development, and the value of participating in clinical studies. […]

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    on June 18, 2019 at 12:02 pm

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACADView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for ACAD with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ACAD are favorable, with net inflows of $3.03 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report. […]

  • Is ACADIA Pharmaceuticals Inc. (ACAD) A Good Stock To Buy?
    on June 12, 2019 at 12:23 am

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]

  • When Will ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Turn A Profit?
    on June 11, 2019 at 10:59 am

    ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the... […]

  • ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
    on June 4, 2019 at 1:00 pm

    ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019 at 1:20 p.m. […]

  • ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
    on May 18, 2019 at 3:00 pm

    ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it will present data from its Phase 2 CLARITY study, which evaluated the efficacy, safety, and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder at the ... […]

  • Edited Transcript of ACAD earnings conference call or presentation 1-May-19 8:30pm GMT
    on May 9, 2019 at 7:57 am

    Q1 2019 ACADIA Pharmaceuticals Inc Earnings Ca […]

  • Why Acadia Pharmaceuticals Stock Slumped in April
    on May 8, 2019 at 7:30 pm

    The contentious drug-pricing debate weighed on Acadia Pharmaceuticals' shares last month. […]

3 days ago

Alignmt LLC

Cultivate your brand value throughout relevant #financial and #industry communities. And remember: never neglect your #stakeholders. #alignmentmap buff.ly/2qhTkRY ... See MoreSee Less

View on Facebook

3 days ago

Alignmt LLC

Got #investors? Want to know what's on their minds? Good #investorrelations starts with them. #alignmentmap buff.ly/2qhTkRY ... See MoreSee Less

View on Facebook

3 days ago

Alignmt LLC

Want to share relevant facts about how your business is developing to the people who back you?

Check out the 7 insightful questions #investorrelations must answer. Check out ways to improve your business results with an #alignmentmap at buff.ly/2HeBtFh
... See MoreSee Less

View on Facebook

3 days ago

Alignmt LLC

What's one thing you wish somebody would have told you before getting into this business? #alignmentmap buff.ly/2qhTkRY ... See MoreSee Less

View on Facebook
Load More...

    Feed has no items.

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

ACADIA Pharmaceuticals Inc.

3611 Valley Centre Drive
Suite 300
San Diego, CA 92130

+1 (858) 558-2871

www.acadia-pharm.com

July 2019
S M T W T F S
« Apr    
 123456
78910111213
14151617181920
21222324252627
28293031  

©2019 ALIGNMT LLC | Alignment Consulting | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account